Stock Track | Harrow Health Plummets 19.59% in Pre-Market on Earnings Miss and Below-Estimate 2026 Revenue Guidance

Stock Track
03/03

Harrow Health Inc. (HROW) experienced a significant pre-market plummet of 19.59% on Tuesday, as the stock opened sharply lower following the release of its latest financial results.

The sharp decline was driven by the company's fourth-quarter earnings report, which revealed earnings per share of $0.17, significantly missing the analyst consensus estimate of $0.38. Furthermore, the ophthalmic drugmaker issued its fiscal 2026 revenue guidance in the range of $350 million to $365 million, which fell below the average analyst estimate of approximately $386 million.

This combination of an earnings shortfall and weaker-than-anticipated forward outlook prompted a sell-off, with the stock extending losses from the previous trading session and underperforming the broader healthcare sector during the pre-market session.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10